{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:58:40Z","timestamp":1791568720339,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bulcan.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:23:50Z","timestamp":1765455830000},"page":"343-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of PRRT for the treatment of pancreatic neuroendocrine tumors: Systematic review and meta-analysis"],"prefix":"10.1016","volume":"113","author":[{"given":"Jun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaxia","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bulcan.2025.10.001_bib0175","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2025.10.001_bib0180","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","article-title":"Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis","volume":"27","author":"Sonbol","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0185","series-title":"Recent innovations in surgical procedures of pancreatic neoplasms","article-title":"Pancreatic neuroendocrine tumors: diagnosis, management, and intraoperative techniques","author":"P\u00e9rez-Saborido","year":"2023"},{"issue":"12","key":"10.1016\/j.bulcan.2025.10.001_bib0190","doi-asserted-by":"crossref","first-page":"e13343","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"7","key":"10.1016\/j.bulcan.2025.10.001_bib0195","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0200","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine and Adrenal Tumors (version 2.2024). [Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf]."},{"issue":"32","key":"10.1016\/j.bulcan.2025.10.001_bib0205","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO Guideline","volume":"41","author":"Del Rivero","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2025.10.001_bib0210","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","article-title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors","volume":"49","author":"Halfdanarson","year":"2020","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.bulcan.2025.10.001_bib0215","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0220","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/JCO.2021.39.15_suppl.4116","article-title":"Efficacy and safety of 177Lu-DOTATATE in patients (pts) with advanced pancreatic neuroendocrine tumors (pNETs): data from the NETTER-R international, retrospective registry","volume":"39","author":"Clement","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0225","unstructured":"Authorization details for Lutathera\u00ae in Europe. [accessed on 23 April 2019; Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lutathera#authorisation-details-section]."},{"key":"10.1016\/j.bulcan.2025.10.001_bib0230","unstructured":"FDA Letter of Approval for LUTATHERA\u00ae [accessed on 23 April 2019; Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2018\/208700Orig1s000ltr.pdf]."},{"issue":"4","key":"10.1016\/j.bulcan.2025.10.001_bib0235","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1530\/EC-21-0027","article-title":"Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE","volume":"10","author":"Pettersson","year":"2021","journal-title":"Endocr Connect"},{"issue":"16","key":"10.1016\/j.bulcan.2025.10.001_bib0240","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0245","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0250","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0255","series-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","first-page":"1","author":"Peterson","year":"2011"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0260","first-page":"S212","article-title":"177Lu-PRRT in pancreatic neuroendocrine tumors: long term follow up in 65 consecutive patients","volume":"41","author":"Sansovini","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.bulcan.2025.10.001_bib0265","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1097\/RLU.0000000000001816","article-title":"Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumors: a long-term-outcome, toxicity, survival, and quality-of-life study","volume":"42","author":"Ballal","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.bulcan.2025.10.001_bib0270","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE [published correction appears in Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):352. doi: 10.1007\/s00259-016-3558-3]","volume":"44","author":"Sansovini","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.bulcan.2025.10.001_bib0275","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12022-020-09623-4","article-title":"Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant peptide receptor radionuclide therapy (PRRT)","volume":"31","author":"Schiavo Lena","year":"2020","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0280","doi-asserted-by":"crossref","first-page":"S954","DOI":"10.1016\/j.annonc.2022.07.1013","article-title":"887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: results of the OCLURANDOM trial","volume":"33","author":"Baudin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0290","first-page":"87","article-title":"Systemic treatment sequences across Europe for patients (pts) with advanced non-functional (NF) well-differentiated pancreatic neuroendocrine tumours (WDpNETs)","volume":"103","author":"Custodio","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.bulcan.2025.10.001_bib0285","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00268-017-4278-y","article-title":"A nationwide population-based study on the survival of patients with pancreatic neuroendocrine tumors in The Netherlands","volume":"42","author":"Genc","year":"2018","journal-title":"World J Surg"},{"issue":"4","key":"10.1016\/j.bulcan.2025.10.001_bib0295","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000348394","article-title":"Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors","volume":"97","author":"Sansovini","year":"2013","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.bulcan.2025.10.001_bib0300","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","article-title":"Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours","volume":"46","author":"van der Zwan","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.bulcan.2025.10.001_bib0305","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/MNM.0000000000001103","article-title":"177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"40","author":"Satapathy","year":"2019","journal-title":"Nucl Med Commun"},{"issue":"2","key":"10.1016\/j.bulcan.2025.10.001_bib0310","doi-asserted-by":"crossref","first-page":"e220290","DOI":"10.1001\/jamanetworkopen.2022.0290","volume":"5","author":"Pusceddu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.bulcan.2025.10.001_bib0315","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00259-020-04873-0","article-title":"177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study","volume":"48","author":"Paganelli","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.bulcan.2025.10.001_bib0320","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2967\/jnumed.123.267363","article-title":"Peptide receptor radionuclide therapy or everolimus in metastatic neuroendocrine tumors: the SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network","volume":"65","author":"Fosse","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0325","doi-asserted-by":"crossref","first-page":"102141","DOI":"10.1016\/j.ctrv.2020.102141","article-title":"Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis [published correction appears in Cancer Treat Rev. 2021 Jun;97:102203. doi: 10.1016\/j.ctrv.2021.102203]","volume":"93","author":"Strosberg","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"1091","key":"10.1016\/j.bulcan.2025.10.001_bib0330","doi-asserted-by":"crossref","first-page":"20180041","DOI":"10.1259\/bjr.20180041","article-title":"Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response","volume":"91","author":"Vaughan","year":"2018","journal-title":"Br J Radiol"},{"issue":"S1","key":"10.1016\/j.bulcan.2025.10.001_bib0335","first-page":"161","article-title":"Secondary endpoint results of the first multicentric randomised phase II trial investigating the antitumour efficacy of 177Lutetium-DOTA-Octreotate (OCLU) in advanced progressive neuroendocrine pancreatic tumour: the OCLURANDOM trial","volume":"37","author":"Baudin","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.bulcan.2025.10.001_bib0340","doi-asserted-by":"crossref","first-page":"S1006","DOI":"10.1016\/j.annonc.2025.08.2334","article-title":"Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase III COMPETE trial","volume":"36","author":"Capdevila","year":"2025","journal-title":"Annals of Oncology"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125005065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125005065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:14:40Z","timestamp":1773177280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125005065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0007455125005065"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.10.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of PRRT for the treatment of pancreatic neuroendocrine tumors: Systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}